Agilent Technologies, Inc. (NYSE:A) Shares Sold by Candriam S.C.A.

Candriam S.C.A. reduced its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 1.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 222,360 shares of the medical research company's stock after selling 4,199 shares during the quarter. Candriam S.C.A. owned about 0.08% of Agilent Technologies worth $29,872,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA increased its stake in Agilent Technologies by 3.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company's stock valued at $2,314,784,000 after buying an additional 525,214 shares during the period. State Street Corp increased its stake in Agilent Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company's stock valued at $1,903,498,000 after buying an additional 158,175 shares during the period. Geode Capital Management LLC increased its stake in Agilent Technologies by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company's stock valued at $1,028,241,000 after buying an additional 30,610 shares during the period. Cantillon Capital Management LLC increased its stake in Agilent Technologies by 0.5% in the 4th quarter. Cantillon Capital Management LLC now owns 3,316,557 shares of the medical research company's stock valued at $445,546,000 after buying an additional 17,627 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Agilent Technologies by 8.7% during the 4th quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company's stock worth $434,625,000 after purchasing an additional 258,358 shares during the period.

Remove Ads

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Agilent Technologies Trading Up 0.0 %

NYSE:A traded up $0.04 on Friday, reaching $126.59. The stock had a trading volume of 2,056,080 shares, compared to its average volume of 1,836,046. The company has a market cap of $36.09 billion, a price-to-earnings ratio of 29.10, a P/E/G ratio of 3.55 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The firm's fifty day moving average is $139.67 and its two-hundred day moving average is $138.69. Agilent Technologies, Inc. has a 12-month low of $121.45 and a 12-month high of $155.35.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Equities analysts expect that Agilent Technologies, Inc. will post 5.57 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be issued a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.78%. Agilent Technologies's payout ratio is currently 22.76%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Barclays raised shares of Agilent Technologies from an "underweight" rating to an "equal weight" rating and upped their price target for the stock from $135.00 to $145.00 in a research note on Monday, February 10th. Citigroup upped their price target on shares of Agilent Technologies to $165.00 and gave the stock a "buy" rating in a research note on Thursday, December 19th. Sanford C. Bernstein lowered their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating on the stock in a research note on Tuesday, November 26th. JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 26th. Finally, StockNews.com raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Agilent Technologies currently has an average rating of "Moderate Buy" and a consensus target price of $146.15.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.